LA JOLLA, October 24, 2025 — The global HIV epidemic remains a significant public health challenge, with approximately 40.8 million people living with HIV-1 worldwide as of 2024. While advances in antiretroviral therapy have transformed HIV into a manageable chronic condition for many, there is still no cure to eradicate the virus from the body. People living with HIV continue to face ongoing health complications, side effects from lifelong treatment, social stigma, and the threat of drug resistance, which complicates long-term management.
New Insights into HIV Integrase Function
One of the most promising strategies for HIV treatment targets the viral enzyme integrase, which facilitates the integration of viral DNA into the host genome—a critical step in the HIV replication cycle. However, recent research from the Salk Institute reveals that integrase also plays an additional, previously underappreciated role. Beyond DNA integration, integrase interacts with viral RNA later in the viral replication process to assist in viral particle assembly and infection of new cells.
Capturing the structural transformations that enable integrase to switch between these functions, scientists used advanced cryo-electron microscopy to generate the first 3D models of integrase in its dual roles. This breakthrough provides new molecular blueprints to guide the design of future therapies that could disrupt integrase’s later-stage interactions with RNA, offering a novel approach to HIV drug development that may overcome issues of drug resistance.
Structural Flexibility of HIV Integrase
HIV integrase displays remarkable adaptability, assembling into a large 16-part complex to integrate viral DNA into host cells and then breaking down into a more compact 4-part complex to interact with viral RNA. According to Dr. Dmitry Lyumkis from Salk, these structural changes, although subtle, are crucial for its multifaceted role in the HIV lifecycle and represent new opportunities for targeted drug design. Understanding these conformational changes could lead to integrase inhibitors that impair both integration and RNA interactions, potentially enhancing treatment effectiveness.
Implications for HIV Treatment and Resistance
Current integrase inhibitors like Dolutegravir target the enzyme during DNA integration but may lose effectiveness as the virus evolves, developing drug resistance. Lyumkis’s earlier research in 2023 detailed how integrase adapts structurally to evade these drugs. The ability to target integrase’s second role with RNA could address this challenge by broadening the therapeutic impact and possibly reducing the emergence of resistance.
With around 1.3 million new HIV infections globally in 2024 and 630,000 AIDS-related deaths—the majority concentrated in sub-Saharan Africa—these scientific advances have substantial public health relevance. According to UNAIDS, approximately 53% of people living with HIV are women and girls, highlighting persistent inequalities in infection rates and access to care. Targeting viral replication more effectively could improve long-term outcomes, reduce viral transmission, and help close the gap in treatment coverage.
Future Research Directions and Public Health Context
The Salk team, including co-first authors Tao Jing and Zelin Shan, plans to confirm integrase’s interaction with viral RNA through further studies and to leverage their structural models to develop next-generation HIV therapies. This work was supported by the National Institutes of Health and philanthropic foundations, underscoring the importance of sustained investment in HIV research.
For people living with HIV, innovations in drug design targeting multiple facets of viral replication offer hope for improved treatment regimens that are less prone to resistance and better tolerated. From a broader perspective, enhancing therapeutic options contributes to global efforts to reduce HIV incidence and mortality, complementing prevention strategies such as education, testing, and access to existing antiretroviral therapy.
The ongoing HIV epidemic demands continuous scientific innovation accompanied by public health strategies focused on equity and access. Integrase-targeting drugs with expanded functionality might play a crucial role in addressing these challenges, ultimately supporting the goal of ending the HIV/AIDS epidemic as a public health threat.
For detailed global HIV statistics and data, readers can consult the UNAIDS fact sheet, which provides current estimates of HIV prevalence, new infections, treatment coverage, and demographic impacts.
